Faculty Opinions recommendation of Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

2019 ◽  
Author(s):  
Jeremy Chataway ◽  
Nevin John
Keyword(s):  
Multiple Sclerosis ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Phase 2 Trial ◽  
Relapsing Multiple Sclerosis

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

2016 ◽  
Vol 15 (11) ◽  
pp. 1148-1159 ◽  
Author(s):  
Ludwig Kappos ◽  
Douglas L Arnold ◽  
Amit Bar-Or ◽  
John Camm ◽  
Tobias Derfuss ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Phase 2 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo ◽  
Phase 2 Trial ◽  
Relapsing Multiple Sclerosis

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

2019 ◽  
Vol 18 (9) ◽  
pp. 845-856 ◽  
Author(s):  
Diego Cadavid ◽  
Michelle Mellion ◽  
Raymond Hupperts ◽  
Keith R Edwards ◽  
Peter A Calabresi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Phase 2 Trial ◽  
Relapsing Multiple Sclerosis

scholarly journals A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Cancer ◽  
2019 ◽  
Vol 125 (14) ◽  
pp. 2445-2454 ◽  
Author(s):  
Robin L. Jones ◽  
Sant P. Chawla ◽  
Steven Attia ◽  
Patrick Schöffski ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase 1 ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document